Tech Company Financing Transactions
Platelet Biogenesis Funding Round
Qiming Ventures, Adena Ventures and eCoast Angels participated in a $10 million Series A funding round for Platelet Biogenesis. The round closed on 6/9/2017.
Transaction Overview
Company Name
Announced On
6/9/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Qiming Ventures (Lead Investor) (Mark McDade)
Vivo Capital (Ed Engleman)
Proceeds Purpose
It will allow us to repeat investigational new drug-enabling studies and establish a scalable industrial process to manufacture clinical grade platelets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
325 Vassar St. 2A
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sam Rasty
Chief Operating Officer
Sven Karlsson
Chief Scientific Officer
Jonathan Thon
Browse more venture capital transactions:
Prev: 6/9/2017: Wavecell venture capital transaction
Next: 6/9/2017: Sente venture capital transaction
Share this article
News on VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs